Adherence with hormonal therapy in women with breast cancer A cross-sectional study in Medellin, Colombia
Article Sidebar
Main Article Content
Background:
Although hormone therapy is a cornerstone in the treatment of breast cancer, low therapeutic adherence is commonly reported, and there is limited evidence on the predictors that contribute to improving adherence in this population.
Objective:
To identify factors associated with adherence to hormone therapy in women with breast cancer, in an oncology clinic in Medellín-Colombia (2019- 2023).
Methods:
Cross-sectional analytical study. Women >18 years old with hormone receptor-positive breast cancer who were undergoing hormone therapy were included. The MMAS-8 scale was used to measure and classify therapeutic adherence into three levels: low, medium, and high. Data was analyzed by multinomial logistic regression.
Results:
One hundred seventy-eight patients with a median age of 64.0 years were included. 50.0% were treated with tamoxifen. The prevalence of non-adherence was 48.9%. 70.2% had adverse effects of hormone therapy, and forgetfulness was the main reason for discontinuation (76.19%). Age was associated with therapeutic adherence, with older women being the most adherent (83.5%). Women with adverse effects, stage III-IV, low socioeconomic and educational level, and a lack of support network had lower therapeutic adherence.
Conclusions:
A high prevalence of moderate and low therapeutic adherence is demonstrated in younger women from lower socioeconomic and educational backgrounds. Preventive strategies are needed to mitigate factors that negatively influence therapeutic adherence.
- Drug-Related Side Effects and Adverse Reactions
- Breast Neoplasms
- Treatment Adherence and Compliance
- Medication Adherence
- Tamoxifen
Katerin Puerta Alzate, Clínica de Oncología Astorga
https://orcid.org/0009-0006-7957-8770
Psicóloga de la Universidad Católica Luis Amigó -FUNLAM-, Medellín-Colombia.
Magister en Epidemiología de la Universidad CES, Medellín-Colombia.
Camila Lema Calidonio, Clínica de Oncología Astorga
https://orcid.org/0000-0002-4382-6676
Médica y Especialista en Epidemiología de la Universidad CES.
Máster en Investigación Biómedica Traslacional, del Institut de Recerca Hospital Vall d'Hebron-Universidad Autónoma de Barcelona, Barcelona-España.
Mauricio Lema Medina, Clínica de Oncología Astorga
https://orcid.org/0000-0001-9346-0361
Médico y cirujano en la Universidad Pontificia Bolivariana - UPB, Medellín-Colombia.
Especialista en Medicina interna en la Universidad de Miami en la ciudad de Miami, Florida-USA. Con entrenamiento adicional en la subespecialidad de Oncología clínica y hematología en la misma Universidad de Miami.
Paula Villa García , Universidad CES
https://orcid.org/0009-0007-2629-5424
Odontóloga de la Institución Universitaria Colegios de Colombia - UNICOC, Bogotá-Colombia . Epidemióloga de la Universidad CES, Medell´ín-Colombia.
Organización Mundial de la Salud. Adherencia a los tratamientos a largo plazo: Pruebas para la acción. OMS; 2004. Citado: 27 de septiembre de 2023. Disponible en: https://www3.paho.org/hq/dmdocuments/2012/WHO-Adherence-Long-Term-Therapies-Spa-2003.pdf
Spencer JC, Reeve BB, Troester MA, Wheeler SB. Factors associated with endocrine therapy non-adherence in breast cancer survivors. Psychooncology. 2020; 29(4): 647-54. https://doi.org/10.1002/pon.5289 PMid:32048400 PMCid: PMC7190446 DOI: https://doi.org/10.1002/pon.5289
Ministerio de Salud y Protección Social. Detección temprana del cáncer de mama. Ministerio de Salud y Protección Social. Boletín de Prensa No 499; 2022. Citado: 30 de enero de 2024. Disponible en: https://www.minsalud.gov.co/Paginas/Deteccion-temprana-del-cancer-de-mama.aspx
Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. NIH. julio de 2012;134(2):459-78. https://doi.org/10.1007/s10549-012-2114-5 PMid:22689091 PMCid: PMC3607286 DOI: https://doi.org/10.1007/s10549-012-2114-5
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008; 10(5): 348-354. https://doi.org/10.1111/j.1751-7176.2008.07572.x PMid:18453793 PMCid: PMC2562622 DOI: https://doi.org/10.1111/j.1751-7176.2008.07572.x
Martinez-Cannon BA, Castro-Sanchez A, Barragan-Carrillo R, de la Rosa PS, Platas A, Fonseca A, et al. Adherence to adjuvant tamoxifen in mexican young women with breast cancer. Patient Prefer Adherence. 2021; 15: 1039-49. https://doi.org/10.2147/PPA.S296747 PMid:34040357 PMCid: PMC8141391 DOI: https://doi.org/10.2147/PPA.S296747
Ali EE, Cheung KL, Lee CP, Leow JL, Yap KY, Chew L. Prevalence and determinants of adherence to oral adjuvant endocrine therapy among breast cancer patients in Singapore. Asia-Pac J Oncol Nurs. 2017; 4(4): 283-9.https://doi.org/10.4103/2347-5625.212864 PMid:28966955 PMCid: PMC5559937 DOI: https://doi.org/10.4103/2347-5625.212864
Elshafie S, Trivedi R, Villa-Zapata LA, Tackett RL, Zaghloul IY, Young HN. Adherence, clinical benefits, and adverse effects of endocrine therapies among women with nonmetastatic breast cancer in developing countries: A systematic review and meta-analysis. Cancer. 131(1):e35550. https://doi.org/10.1002/cncr.35550 PMid:39235037 PMCid: PMC11694169 DOI: https://doi.org/10.1002/cncr.35550
Brito C, Portela MC, Vasconcellos MTL de. Factors associated to persistence with hormonal therapy in women with breast cancer. Rev Saude Publica. 2014; 48(2): 284-95. https://doi.org/10.1590/S0034-8910.2014048004799 PMid:24897050 PMCid: PMC4206152 DOI: https://doi.org/10.1590/S0034-8910.2014048004799
Brito C, Portela MC, de Vasconcellos MTL. Adherence to hormone therapy among women with breast cancer. BMC Cancer. 2014; 14(1): 397. https://doi.org/10.1186/1471-2407-14-397 PMid:24893670 PMCid: PMC4057651 DOI: https://doi.org/10.1186/1471-2407-14-397
Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009; 27(21): 3445-51. https://doi.org/10.1200/JCO.2008.19.2419 PMid:19451445 PMCid: PMC2717752 DOI: https://doi.org/10.1200/JCO.2008.19.2419
Xu H, Jin F, Zhang XJ, Wang DQ, Yu SF, Wang AP. Adherence status to adjuvant endocrine therapy in chinese women with early breast cancer and its influencing factors: A cross-sectional survey. Cancer Med. 2020; 9(11): 3703-13. https://doi.org/10.1002/cam4.3017 PMid:32237070 PMCid: PMC7286448 DOI: https://doi.org/10.1002/cam4.3017
Villarreal-Garza C, Mesa-Chavez F, Ferrigno AS, De la Garza-Ramos C, Fonseca A, Villanueva-Tamez K, et al. Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico. Breast. 2021; 59: 8-15. https://doi.org/10.1016/j.breast.2021.05.013 PMid:34116366 PMCid: PMC8192863 DOI: https://doi.org/10.1016/j.breast.2021.05.013
Sella T, Poorvu PD, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, et al. Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer. 2021; 127(16): 2888-94. https://doi.org/10.1002/cncr.33596 PMid:33886123 PMCid: PMC8351455 DOI: https://doi.org/10.1002/cncr.33596
Cluze C, Rey D, Huiart L, BenDiane MK, Bouhnik AD, Berenger C, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol. 2012; 23(4): 882-90. https://doi.org/10.1093/annonc/mdr330 PMid:21788360 DOI: https://doi.org/10.1093/annonc/mdr330
Liu Y, Malin JL, Diamant AL, Thind A, Maly RC. Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat. 2013; 137(3): 829-36. https://doi.org/10.1007/s10549-012-2387-8 PMid:23263740 PMCid: PMC3553239 DOI: https://doi.org/10.1007/s10549-012-2387-8
Koni AA, Suwan BA, Nazzal MA, Sleem A, Daifallah A, Allah MH, et al. Adherence to oral anticancer hormonal therapy in breast cancer patients and its relationship with treatment satisfaction: an important insight from a developing country. BMC Womens Health. 2023; 23(1): 1-12. https://doi.org/10.1186/s12905-023-02276-5 PMid:36941628 PMCid: PMC10026465 DOI: https://doi.org/10.1186/s12905-023-02276-5
Morisky DE. Morisky Scale. Adherence. 2023. Citado 10 de diciembre de 2024.Disponible en: http://www.moriskyscale.com/2/archives/05-2023
Castaño AL, Chabur KJ, Hernández MG, Herreño MF. La red de apoyo social como soporte efectivo en la adherencia y finalización del tratamiento oncológico. Trabajo de grado. Enfermería, Fundación Universitaria de Ciencias de la Salud: Bogotá; 2017. Disponible en: https://repositorio.fucsalud.edu.co/handle/001/2630
Downloads
Accepted 2025-06-05
Published 2025-06-16
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use